ACEI或ARB治疗新型冠状病毒肺炎合并高血压的病情预后观察  

Clinical Observation of ACEI/ARB in Treating New Coronavirus Pneumonia Complicated with Hypertension

作　　者：陈宇宁[1] 李博文 严萍[1] 

机构地区：[1]福建中医药大学附属第二人民医院,福建 福州 [2]福建中医药大学附属康复医院,福建 福州

出　　处：《医学诊断》2021年第4期193-197,共5页Medical Diagnosis

摘　　要：目的:观察血管紧张素转换酶抑制药(ACEI)或血管紧张素受体阻滞药(ARB)治疗新型冠状病毒肺炎合并高血压的病情预后影响。方法:选取2020年1月至2020年3月在武汉金银潭医院诊断及治疗的新型冠状病毒肺炎合并高血压患者68例进行回顾性分析。根据是否使用ACEI/ARB降压治疗,分为ACEI/ARB组(n = 31)和对照组(n = 37)。对其进行序贯器官功能衰竭(SOFA)评分、Murray肺损伤评分及心血管不良事件(MACE)发生率统计。分析两组SOFA评分、Murray肺损伤评分及MACE发生率的差异。结果:两组患者的SOFA评分、Murray评分及MACE发生率差异均无统计学意义(P 】0.05)。结论:新型冠状病毒肺炎合并高血压的患者使用ACEI/ARB降压对其预后无特殊影响。Objective: To observe the prognosis of New Coronavirus pneumonia complicated with hypertension by angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). Methods: 68 cases of New Coronavirus pneumonia complicated with hypertension diagnosed and treated in Wuhan Jinyintan Hospital from January 2020 to March 2020 were retrospectively analyzed. They were divided into ACEI/ARB group (n = 31) and control group (n = 37) according to whether ACEI/ARB was used in anti-hypertension treatment. Sequential organ failure assessment score (SOFA), Murray lung injury score and incidence of adverse cardiovascular events (MACE) were statistically counted. The differences of SOFA score, Murray lung injury score and MACE incidence be-tween the two groups were analyzed. Results: There was no statistical significance in the difference of SOFA score, Murray score and incidence of MACE between the two groups (P >0.05). Conclusion: ACEI/ARB has no adverse effect in anti-hypertension treatment of patients with New Coronavirus pneumonia complicated with hypertension.

关 键 词：新型冠状病毒肺炎 高血压 血管紧张素转换酶抑制药 血管紧张素受体阻滞药 

分 类 号：R54[医药卫生—心血管疾病]